| Name | Title | Contact Details |
|---|
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient`s own T cells harvested from the patient`s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells.
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
Thrive Bioscience`s unique solutions increase the speed, quality, and cost-effectiveness of drug discovery and basic research while enabling the delivery of new therapies through improving the cell culture and stem cell culture processes.